Diskussionsleitung: T. Arentz (Bad Krozingen), P. Sommer (Bad Oeynhausen)
(P1915) | 3D Mapping of Phrenic Nerve Course for Radiofrequency Pulmonary Vein Isolation | |
M. Bohnen, R. Weber, J. Minners, M. Eichenlaub, A. S. Jadidi, B. Müller-Edenborn, F.-J. Neumann, T. Arentz, H. Lehrmann (Bad Krozingen) | ||
(P1916) | Outcomes in patients experiencing complications associated with atrial fibrillation ablation: data from the German Ablation Registry | |
S. Kany, K.-H. Kuck, J. Brachmann, D. Andresen, S. Willems, L. Eckardt, M. Hochadel, J. Senges, A. Metzner, A. Rillig (Hamburg, Coburg, Berlin, Münster, Ludwigshafen am Rhein) | ||
(P1917) | Safety and feasibility of catheter ablations in patients with bleeding disorders | |
M. Feher, B. Kirstein, A. Keelani, H. L. Phan, A. Traub, C. Eitel, J. Vogler, K.-H. Kuck, R. R. Tilz, C.-H. Heeger (Lübeck, Hamburg) | ||
(P1918) | Impact of single vs. multi-sensor esophageal temperature probe for cryoballoon pulmonary vein isolation | |
H. L. Phan, C.-H. Heeger, A. Keelani, B. Kirstein, M. Feher, A. Traub, S. Hatahet, C. Eitel, J. Vogler, K.-H. Kuck, R. R. Tilz (Lübeck, Hamburg) | ||
(P1919) | Management of retroperitoneal hematoma in MR-guided electrophysiological study | |
J. Tomala, S. Ulbrich, L. Pu, J. Mayer, A. M. Zedda, U. Richter, Y. Huo, A. Linke, T. Gaspar (Dresden) | ||
(P1920) | Silent cerebral lesions after very high power short duration ablation compared to standard power ablation for PVI – the randomized Power Pulse MRI trial | |
M. Kottmaier, L. V. Förschner, M.-A. Popa, T. Reents, F. Bourier, F. Bahlke, H. Krafft, S. J. Maurer, S. Lengauer, F. Englert, S. Brandhorst, S. Kathan, G. Heßling, I. Deisenhofer (München) | ||
(P1921) | Niedrige Inzidenz von stummen cerebralen Ischämien bei der Pulmonalvenenisolation mit „high-Power, Short-Duration“ mit 50 und 90 Watt | |
M. Cacic, K. Sonne, A. Berkovitz, K. Nentwich, E. Ene, G. Simu, C. Munoz Perez, S. Tskhadadze, T. Deneke (Bad Neustadt a. d. Saale) | ||
(P1922) | Catheter ablation and electrical cardioversion in nonagenarians: Which patients should be treated? Is it safe? | |
F. Bahlke, S. Preisendörfer, S. J. Maurer, F. Englert, H. Krafft, M.-A. Popa, M. Kottmaier, E. Risse, K. Wimbauer, S. Lengauer, F. Bourier, T. Reents, G. Heßling, I. Deisenhofer (München) |